Cargando…

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

PURPOSE: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Yolanda, Cajaraville, Gerardo, Virizuela, Juan Antonio, Álvarez, Rosa, Muñoz, Andrés, Olariaga, Olatz, Tamés, María José, Muros, Begoña, Lecumberri, María Jose, Feliu, Jaime, Martínez, Purificación, Adansa, Juan Carlos, Martínez, María José, López, Rafael, Blasco, Ana, Gascón, Pere, Calvo, Virginia, Luna, Pablo, Montalar, Joaquín, Del Barrio, Patricia, Tornamira, María Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519584/
https://www.ncbi.nlm.nih.gov/pubmed/26081597
http://dx.doi.org/10.1007/s00520-015-2809-3
_version_ 1782383518335107072
author Escobar, Yolanda
Cajaraville, Gerardo
Virizuela, Juan Antonio
Álvarez, Rosa
Muñoz, Andrés
Olariaga, Olatz
Tamés, María José
Muros, Begoña
Lecumberri, María Jose
Feliu, Jaime
Martínez, Purificación
Adansa, Juan Carlos
Martínez, María José
López, Rafael
Blasco, Ana
Gascón, Pere
Calvo, Virginia
Luna, Pablo
Montalar, Joaquín
Del Barrio, Patricia
Tornamira, María Victoria
author_facet Escobar, Yolanda
Cajaraville, Gerardo
Virizuela, Juan Antonio
Álvarez, Rosa
Muñoz, Andrés
Olariaga, Olatz
Tamés, María José
Muros, Begoña
Lecumberri, María Jose
Feliu, Jaime
Martínez, Purificación
Adansa, Juan Carlos
Martínez, María José
López, Rafael
Blasco, Ana
Gascón, Pere
Calvo, Virginia
Luna, Pablo
Montalar, Joaquín
Del Barrio, Patricia
Tornamira, María Victoria
author_sort Escobar, Yolanda
collection PubMed
description PURPOSE: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints. RESULTS: Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT(3)) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients’ diary. CONCLUSION: Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-015-2809-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4519584
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-45195842015-08-03 Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study Escobar, Yolanda Cajaraville, Gerardo Virizuela, Juan Antonio Álvarez, Rosa Muñoz, Andrés Olariaga, Olatz Tamés, María José Muros, Begoña Lecumberri, María Jose Feliu, Jaime Martínez, Purificación Adansa, Juan Carlos Martínez, María José López, Rafael Blasco, Ana Gascón, Pere Calvo, Virginia Luna, Pablo Montalar, Joaquín Del Barrio, Patricia Tornamira, María Victoria Support Care Cancer Original Article PURPOSE: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints. RESULTS: Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT(3)) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients’ diary. CONCLUSION: Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-015-2809-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-06-17 2015 /pmc/articles/PMC4519584/ /pubmed/26081597 http://dx.doi.org/10.1007/s00520-015-2809-3 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Escobar, Yolanda
Cajaraville, Gerardo
Virizuela, Juan Antonio
Álvarez, Rosa
Muñoz, Andrés
Olariaga, Olatz
Tamés, María José
Muros, Begoña
Lecumberri, María Jose
Feliu, Jaime
Martínez, Purificación
Adansa, Juan Carlos
Martínez, María José
López, Rafael
Blasco, Ana
Gascón, Pere
Calvo, Virginia
Luna, Pablo
Montalar, Joaquín
Del Barrio, Patricia
Tornamira, María Victoria
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
title Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
title_full Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
title_fullStr Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
title_full_unstemmed Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
title_short Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
title_sort incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: advice (actual data of vomiting incidence by chemotherapy evaluation) study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519584/
https://www.ncbi.nlm.nih.gov/pubmed/26081597
http://dx.doi.org/10.1007/s00520-015-2809-3
work_keys_str_mv AT escobaryolanda incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT cajaravillegerardo incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT virizuelajuanantonio incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT alvarezrosa incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT munozandres incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT olariagaolatz incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT tamesmariajose incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT murosbegona incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT lecumberrimariajose incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT feliujaime incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT martinezpurificacion incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT adansajuancarlos incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT martinezmariajose incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT lopezrafael incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT blascoana incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT gasconpere incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT calvovirginia incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT lunapablo incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT montalarjoaquin incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT delbarriopatricia incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy
AT tornamiramariavictoria incidenceofchemotherapyinducednauseaandvomitingwithmoderatelyemetogenicchemotherapyadviceactualdataofvomitingincidencebychemotherapyevaluationstudy